<DOC>
	<DOCNO>NCT01710046</DOCNO>
	<brief_summary>There cell skin blood human chronic moderate severe plaque psoriasis specific activity may determine effectiveness treatment . These activity may describe obtain sample skin blood analyze use variety test .</brief_summary>
	<brief_title>Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description>The final subject Cohort 1 complete study 19-Nov-2013 ( LSLV date ) . Because study analysis novel exploratory , require extensive analysis study team external expert . As result analysis determine 21-July-2014 data Cohort 1 sufficiently definitive enrollment Cohort 2 would justify . Since decision result LSLV Cohort 1 become LSLV study , full data analysis reporting project complete within 12 Months LSLV . The final analysis final reporting plan complete 18-Feb-2015 . Results data anticipate release April 2015 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Adults 18 year age diagnosis chronic moderate severe plaque psoriasis least 12 month ; generally good health ; stable dose nonprohibited medication ; able stop current psoriasis therapy ( systemic topical ) several week prior study participation . Serious underlying disease include viral disorder hepatitis HIV skin condition would interfere skin biopsy evaluation psoriasis ; condition could interfere drug absorption oral administration ; history malignancy autoimmune disease . Use oral injected corticosteroid ( steroid ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>plaque psoriasis</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>biopsy</keyword>
	<keyword>Janus Kinase</keyword>
	<keyword>randomize placebo control clinical trial</keyword>
	<keyword>psoriasis vulgaris</keyword>
</DOC>